Abstract: Disclosed are novel compounds of Chemical Formula 1, optical isomers of the compounds, and pharmaceutically acceptable salts of the compounds or the optical isomers. The compounds, isomers, and salts exhibit excellent activity as GLP-1 receptor agonists. In particular, they, as GLP-1 receptor agonists, exhibit excellent glucose tolerance, thus having a great potential to be used as therapeutic agents for metabolic diseases. Moreover, they exhibit excellent pharmacological safety for cardiovascular systems.

Abstract: The present invention relates to a composition for preventing or treating periodontal diseases comprising a Bacillus velezensis strain, or a culture medium or culture supernatant thereof as an active ingredient, and more particularly, to a pharmaceutical composition for preventing or treating periodontal diseases or halitosis comprising a Bacillus velezensis strain, or a culture medium or culture supernatant thereof as an active ingredient, and a quasi-drug composition, a health functional food composition and a food composition for preventing or improving periodontal diseases and halitosis comprising a Bacillus velezensis strain, or a culture medium or culture supernatant thereof as an active ingredient.

Abstract: The present invention relates to a Bacillus subtilis ID-A05 strain and a composition including same, and more specifically, to: a novel Bacillus subtilis strain effective for both treating cavities and periodontal diseases and alleviating halitosis; a culture medium of the Bacillus subtilis strain; a culture supernatant of the Bacillus subtilis strain; a pharmaceutical composition for treating cavities and periodontal diseases, the pharmaceutical composition containing, as an active ingredient, the Bacillus subtilis strain or a culture medium or culture supernatant thereof; a quasi-drug composition for preventing or alleviating cavities, periodontal diseases, and halitosis, the quasi-drug composition containing, as an active ingredient, the Bacillus subtilis strain or a culture medium or culture supernatant thereof; a health functional food composition; and a food composition.

Abstract: The present invention relates to novel Bacillus velezensis strains ID-A01, ID-A02, ID-A03, and ID-A04 and use thereof, and more particularly, to novel Bacillus velezensis strains with all effects of treating cavities and periodontal diseases and improving halitosis, culture media of the Bacillus velezensis strains, culture supernatants of the Bacillus velezensis strains, a pharmaceutical composition for treating cavities, periodontal diseases or halitosis comprising the Bacillus velezensis strain, or a culture medium or culture supernatant thereof as an active ingredient, and a quasi-drug composition, a health functional food composition and a food composition for preventing or improving cavities, periodontal diseases or halitosis comprising the Bacillus velezensis strain, or a culture medium or culture supernatant thereof as an active ingredient.

Abstract: The present invention provides a novel compound represented by Chemical Formula 2, or a pharmaceutically acceptable salt thereof. The novel compound according to the present invention exhibits an excellent acid secretion inhibitory effect.

Abstract: Disclosed are novel compounds of Chemical Formula 1, optical isomers of the compounds, and pharmaceutically acceptable salts of the compounds or the optical isomers. The compounds, isomers, and salts exhibit excellent activity as GLP-1 receptor agonists. In particular, they, as GLP-1 receptor agonists, exhibit excellent glucose tolerance, thus having a great potential to be used as therapeutic agents for metabolic diseases. Moreover, they exhibit excellent pharmacological safety for cardiovascular systems.

Abstract: Disclosed are novel compounds of Chemical Formula 1, optical isomers of the compounds, and pharmaceutically acceptable salts of the compounds or the optical isomers. The compounds, isomers, and salts exhibit excellent activity as GLP-1 receptor agonists. In particular, they, as GLP-1 receptor agonists, exhibit excellent glucose tolerance, thus having a great potential to be used as therapeutic agents for metabolic diseases. Moreover, they exhibit excellent pharmacological safety for cardiovascular systems.

Abstract: Disclosed are novel compounds of Chemical Formula 1, optical isomers of the compounds, and pharmaceutically acceptable salts of the compounds or the optical isomers. The compounds, isomers, and salts exhibit excellent activity as GLP-1 receptor agonists. In particular, they, as GLP-1 receptor agonists, exhibit excellent glucose tolerance, thus having a great potential to be used as therapeutic agents for metabolic diseases. Moreover, they exhibit excellent pharmacological safety for cardiovascular systems.

Abstract: The present invention provides novel compounds of chemical formula 1, optical isomers of the compounds, or a pharmaceutically acceptable salts of the compounds, or the optical isomers. The compounds, isomers, and salts exhibits excellent activity as GLP-1 receptor agonists. Particularly, they, as GLP-1 receptor agonists, exhibit excellent glucose tolerance, thus having a great potential to be used therapeutic agents for metabolic diseases. In addition, they exhibits excellent pharmacological safety for cardiovascular systems.

Abstract: A method for preventing, ameliorating, or treating stress or depression includes administering a subject in need thereof a composition including a medicinal herb extract as an effective ingredient. Tt is shown that an extract of Hibiscus syriacus flower and an extract of Hibiscus syriacus root have an activity of protecting nerve cells, can lower the expression level of an inflammatory factor, which is increased by stress, and is effective for depression caused by stress.

Abstract: A health functional food composition and a pharmaceutical composition for preventing or ameliorating a non-alcoholic fatty liver disease include an extract of Dolichos lablab Linne as an active ingredient. The extract of Dolichos lablab Linne, being an active ingredient, effectively reduces accumulation of triglyceride in hepatocarcinoma cell line (HepG2). Therefore, the compositions are used for functional foods and medicines for the prevention or amelioration of non-alcoholic fatty liver.

Abstract: A health functional food composition and a pharmaceutical composition for preventing or ameliorating a non-alcoholic fatty liver disease include an extract of Dolichos lablab Linne as an active ingredient. The extract of Dolichos lablab Linne, being an active ingredient, effectively reduces accumulation of triglyceride in hepatocarcinoma cell line (HepG2). Therefore, the compositions are used for functional foods and medicines for the prevention or amelioration of non-alcoholic fatty liver.

Abstract: The present invention relates to a composition, containing tyndallized lactobacillus dead cells as an active ingredient, for skin moisturizing or wrinkle improvement. The effect of the tyndallized lactobacillus dead cells on skin moisturizing and wrinkle improvement, which are deteriorated by ultraviolet radiation, was checked. As a result, it was confirmed that the amount of moisture evaporating from the skin was reduced and the amount of moisture contained in the skin was increased. In addition, it was confirmed that the epidermis thickness was reduced and the expression levels of wrinkle-related proteins were reduced. Therefore, the composition of the present invention improves the damage of the skin barriers, which is caused by ultraviolet radiation, thereby suppressing the loss of skin moisture or the wrinkle formation.